尼拉帕利治疗晚期卵巢癌的快速卫生技术评估

A RAPID Health Technology Assessment of Niraparib for the Treatment of Advanced Ovarian Cancer

目的评价尼拉帕利用于治疗晚期卵巢癌患者的有效性、安全性和经济性,为临床治疗提供循证医学证据。方法通过计算机检索中国知网、万方、PubMed、Embase、the Cochrane Library等中英文数据库。由2位评价者分别根据纳入与排除标准进行文献筛选、资料提取和分析。结果从检索到的912篇文献中筛选纳入2篇卫生技术评估(HTA)报告、12篇SR/Meta分析、6篇经济学研究。尼拉帕利用于初治晚期卵巢癌患者的维持治疗及铂敏感复发性卵巢癌患者的维持治疗,均可显著延长患者的无进展生存期(PFS)。安全性方面,尼拉帕利治疗可显著增加血液学不良反应的风险,但患者生存质量无明显降低。结论尼拉帕利用于晚期卵巢癌患者的维持治疗可显著延长患者的PFS,具有良好的有效性和可接受的安全性。

OBJECTIVE To evaluate the effectiveness,safety and economics of niraparib in advanced ovarian cancer patients,and to provide evidence for rational use.METHODS Literature search was performed in Chinese and English database such as CNKI,Wanfang,Pubmed,Embase,and the Cochrane Library.Two reviewers identified literatures,extracted data base on the inclusion and exclusion criteria independently.RESULTS A total of 912 literatures were found through the search,and finally included 2 HTA reports,12 systematic review/Meta-analysis and 6 pharmacoeconomic studies.Compared with placebo,niraparib significantly prolonged progression-free survival(PFS)in maintenance treatment of newly diagnosed advanced ovarian cancer and platinum-sensitive recurrent ovarian cancer.In terms of safety,niraparib treatment can significantly increase the risk of hematological adverse reactions,but the patient's quality of life does not significantly decrease.CONCLUSION Niraparib in the maintenance treatment of advanced ovarian cancer can significantly prolong the PFS of patients,with good effectiveness and acceptable safety.